*Generated: 2026-02-18 23:39*

## News & Sentiment: Neuronetics, Inc. (STIM)
*Sources: Finviz (100), Google News (35), yfinance (10) | Method: VADER | Deep Dives: 5*

### Headlines (Top 30, Deduplicated)
| Date | Source | Headline | Sentiment | Score | Catalysts |
| :--- | :--- | :--- | :--- | :--- | :--- |
| 2026-02-13 | Simply Wall St. | Assessing Neuronetics (STIM) Valuation After Positive Cash F... | Positive | +0.78 | Earnings |
| 2026-02-11 | Benzinga | Neuronetics (STIM) Stock Rises 41% After Hours: What's Going... | Neutral | +0.00 | — |
| 2026-02-11 | ChartMill | STIM Stock Price, Forecast & Analysis - NEURONETICS INC (NAS... | Neutral | +0.00 | — |
| 2026-02-11 | MT Newswires | Top Midday Gainers | Positive | +0.20 | — |
| 2026-02-10 | GlobeNewswire | Neuronetics Announces Selected Preliminary Unaudited Fourth ... | Neutral | +0.00 | — |
| 2026-02-10 | Stock Titan | Neuronetics lifts 2025 revenue 99%, books positive Q4 operat... | Positive | +0.56 | Earnings |
| 2026-01-07 | simplywall.st | There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted ... | Negative | -0.26 | Earnings |
| 2025-12-24 | Trefis | Would You Still Hold Neuronetics Stock If It Fell Another 30... | Neutral | +0.00 | — |
| 2025-12-17 | Simply Wall St. | Neuronetics (NASDAQ:STIM) adds US$25m to market cap in the p... | Neutral | +0.00 | — |
| 2025-12-13 | simplywall.st | Would Neuronetics (NASDAQ:STIM) Be Better Off With Less Debt... | Positive | +0.18 | — |
| 2025-11-21 | 富途牛牛 | Neuronetics, Inc.'s (NASDAQ:STIM) 36% Loss Last Week Hit Bot... | Negative | -0.05 | — |
| 2025-11-20 | GlobeNewswire | Neuronetics to Participate at the Piper Sandler 37th Annual ... | Neutral | +0.00 | — |
| 2025-11-18 | Benzinga | Top 3 Health Care Stocks Which Could Rescue Your Portfolio I... | Positive | +0.81 | — |
| 2025-11-17 | Quiver Quantita | $STIM stock is down 18% today. Here's what we see in our dat... | Neutral | +0.00 | — |
| 2025-11-12 | GlobeNewswire | TRICARE West Expands NeuroStar TMS Coverage to Include Adole... | Negative | -0.73 | — |
| 2025-11-12 | Stock Titan | Neuronetics (NASDAQ: STIM): TRICARE West covers NeuroStar TM... | Neutral | +0.00 | — |
| 2025-11-06 | Yahoo Finance | Here's What Analysts Are Forecasting For Neuronetics, Inc. (... | Neutral | +0.00 | — |
| 2025-11-06 | simplywall.st | The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Ar... | Neutral | +0.00 | — |
| 2025-11-05 | simplywall.st | Neuronetics (STIM): Ongoing Losses Challenge Bullish Narrati... | Positive | +0.05 | Earnings |
| 2025-11-04 | GuruFocus.com | Neuronetics Inc (STIM) Q3 2025 Earnings Call Highlights: Rev... | Neutral | +0.00 | Earnings, Corporate |
| 2025-11-04 | Zacks | Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates | Negative | -0.49 | Earnings |
| 2025-11-04 | Associated Pres | Neuronetics: Q3 Earnings Snapshot | Neutral | +0.00 | Earnings |
| 2025-11-04 | GlobeNewswire | Neuronetics Reports Third Quarter 2025 Financial and Operati... | Neutral | +0.00 | Corporate |
| 2025-11-04 | Yahoo Finance | Neuronetics (STIM): Losses Worsen Despite Revenue Growth Out... | Negative | -0.80 | Earnings |
| 2025-11-03 | GuruFocus.com | Neuronetics Inc (STIM) Q3 2025: Everything You Need To Know ... | Neutral | +0.00 | Earnings |
| 2025-10-31 | GlobeNewswire | Neuronetics Reports Inducement Grant Under Nasdaq Listing Ru... | Positive | +0.36 | — |
| 2025-10-30 | GlobeNewswire | Neuronetics Announces Three-Year Exclusive Partnership with ... | Positive | +0.78 | — |
| 2025-10-21 | GlobeNewswire | Neuronetics to Report Third Quarter 2025 Financial and Opera... | Neutral | +0.00 | — |
| 2025-10-21 | Quiver Quantita | Neuronetics, Inc. Announces Q3 2025 Financial Results Releas... | Neutral | +0.00 | — |
| 2025-10-16 | DirectorsTalk I | Neuronetics, Inc. (STIM) Stock Analysis: Exploring a 113.82%... | Neutral | +0.00 | Regulatory |

### Sentiment Summary
| Metric | Value |
| :--- | :--- |
| Articles Analyzed | 30 |
| Positive | 8 (27%) |
| Neutral | 17 (57%) |
| Negative | 5 (17%) |
| Average Score | +0.046 |
| Overall Sentiment | **Neutral** |
| Total Unique Headlines | 116 |

### Detected Catalysts
| Category | Count | Headlines |
| :--- | :--- | :--- |
| Earnings | 9 | Assessing Neuronetics (STIM) Valuation A..; Neuronetics lifts 2025 revenue 99%, book.. |
| Corporate | 2 | Neuronetics Inc (STIM) Q3 2025 Earnings ..; Neuronetics Reports Third Quarter 2025 F.. |
| Regulatory | 1 | Neuronetics, Inc. (STIM) Stock Analysis:.. |

### Deep Dive Articles

#### Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
*Source: Benzinga | Date: 2026-02-11 | Sentiment: Positive (+0.80)*

> Neuronetics Inc.(NASDAQ:STIM) shares soared 41.08% to $2.06 in after-hours trading on Tuesday following preliminary fourth-quarter 2025 financial results.

> The medical technology company reported fourth-quarter 2025 revenue of $41.8 million, up 23% on an adjusted pro forma basis and 86% compared with fourth-quarter 2024 on an as-reported basis.

> Revenue from the NeuroStar system, the first transcranial magnetic stimulation (TMS) device to receiveFood and Drug Administrationclearance, was $18.3 million, up 9% pro forma, while clinic revenue reached $23.5 million, up 37% pro forma.

> According to the company, it shipped 49NeuroStar Advanced Therapysystems and generated positive operating cash flow of $0.9 million during the quarter, in line with previously issued guidance.

> Full-year 2025 revenue totaled $149.2 million, up 15% on an adjusted pro forma basis.

**Catalysts:** Earnings

#### Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
*Source: GlobeNewswire | Date: 2026-02-10 | Sentiment: Positive (+0.99)*

> All values provided represent preliminary unaudited results

> MALVERN, Pa., Feb.  10, 2026  (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced selected preliminary unaudited financial results for the fourth quarter and full-year 2025.

> “We wrapped up 2025 with strong commercial execution during the fourth quarter across both segments of the business. We continue to see solid demand for NeuroStar systems and are proud to see our NeuroStar customers helping more patients in need. Our clinic business had another exciting quarter as we continue to optimize our operations while also driving significant revenue growth,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics. “Importantly, we translated this strong revenue performance into positive operating cash flow during the quarter and maintained the strength of our balance sheet as we move into 2026.”

> Selected Preliminary, Unaudited Fourth Quarter 2025 Financial Results

> This press release assumes the acquisition between Greenbrook and Neuronetics occurred on January 1, 2024 and includes the following adjustments: The addition of assumed sales to Greenbrook through December 31, 2024 following the acquisition, the elimination of all Greenbrook sales and assumed sales for the year ended December 31, 2024 and the closure of all non-performing Greenbrook clinics on January 1, 2024.

**Catalysts:** Earnings, Corporate

#### Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
*Source: GlobeNewswire | Date: 2025-11-20 | Sentiment: Negative (-0.96)*

> MALVERN, Pa., Nov.  20, 2025  (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37thAnnual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 12:30 p.m. (ET) the same day. The presentation will be available via the conference portal to registered attendees.

> Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

> The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

> Mike Vallie or Mark KlausnerICR Healthcare443-213-0499[email protected]

**Catalysts:** Corporate, Equity

#### TRICARE West Expands NeuroStar TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
*Source: GlobeNewswire | Date: 2025-11-12 | Sentiment: Positive (+0.98)*

> New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States

> MALVERN, Pa., Nov.  12, 2025  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar®Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical policy to include TMS coverage for adolescents aged 15 and older.

> TRICARE coverage is primarily used by active and retired military service members and their eligible family members. This policy update, effective immediately, applies to TRICARE beneficiaries in the following states: Alaska, Arizona, Arkansas, California, Colorado, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Minnesota, Missouri, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington, Wisconsin, and Wyoming.

> “TRICARE’s decision to expand coverage for TMS to adolescents is a significant step forward in ensuring that younger patients struggling with depression now have access to this life-changing treatment,” said Keith J. Sullivan, President and CEO of Neuronetics, Inc. “We applaud TRICARE and TriWest for recognizing the importance of providing innovative, evidence-based care to those who need it most, and we remain committed to working with providers and policymakers to expand adolescent access to TMS nationwide.”

> "The demands of military life can create unique stressors for the children of service members, increasing their vulnerability to depression and other mental health challenges,” said Geoffrey Grammer, MD, Chief Medical Officer of Neuronetics and retired U.S. Army Colonel. “By expanding coverage to include NeuroStar TMS, TriWest is taking a meaningful step toward ensuring that the sons and daughters of our active-duty and retired military heroes receive the care and support that honors their families’ service to our nation."

**Catalysts:** Earnings, Corporate, Equity

#### Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates
*Source: Zacks | Date: 2025-11-04 | Sentiment: Negative (-0.08)*

> Neuronetics (STIM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

> This quarterly report represents an earnings surprise of -18.18%. A quarter ago, it was expected that this medical device company focused on psychiatric disorders would post a loss of $0.08 per share when it actually produced a loss of $0.15, delivering a surprise of -87.5%.

> Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

> Neuronetics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $37.3 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.21%. This compares to year-ago revenues of $18.53 million. The company has topped consensus revenue estimates three times over the last four quarters.

> The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

**Catalysts:** Earnings, Corporate
